vs
Side-by-side financial comparison of Ball Corporation (BALL) and Kenvue (KVUE). Click either name above to swap in a different company.
Kenvue is the larger business by last-quarter revenue ($3.8B vs $3.6B, roughly 1.0× Ball Corporation). Kenvue runs the higher net margin — 8.7% vs 5.7%, a 3.0% gap on every dollar of revenue. On growth, Ball Corporation posted the faster year-over-year revenue change (16.3% vs 3.2%). Kenvue produced more free cash flow last quarter ($744.0M vs $-938.0M). Over the past eight quarters, Ball Corporation's revenue compounded faster (10.3% CAGR vs -1.5%).
Ball Corporation is a leading global provider of innovative, sustainable aluminum packaging solutions for beverage, personal care, and household product brands. It also operates an aerospace segment that delivers advanced technologies, systems, and services to government and commercial customers worldwide, prioritizing environmental responsibility and product reliability across all operations.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
BALL vs KVUE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $3.8B |
| Net Profit | $205.0M | $330.0M |
| Gross Margin | — | 56.5% |
| Operating Margin | — | 14.2% |
| Net Margin | 5.7% | 8.7% |
| Revenue YoY | 16.3% | 3.2% |
| Net Profit YoY | 14.5% | 12.6% |
| EPS (diluted) | $0.77 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.3B | $3.8B | ||
| Q3 25 | $3.4B | $3.8B | ||
| Q2 25 | $3.3B | $3.8B | ||
| Q1 25 | $3.1B | $3.7B | ||
| Q4 24 | $2.9B | $3.7B | ||
| Q3 24 | $3.1B | $3.9B | ||
| Q2 24 | $3.0B | $4.0B |
| Q1 26 | $205.0M | — | ||
| Q4 25 | $200.0M | $330.0M | ||
| Q3 25 | $321.0M | $398.0M | ||
| Q2 25 | $215.0M | $420.0M | ||
| Q1 25 | $179.0M | $322.0M | ||
| Q4 24 | $-30.0M | $293.0M | ||
| Q3 24 | $199.0M | $383.0M | ||
| Q2 24 | $159.0M | $58.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.5% | ||
| Q3 25 | — | 59.1% | ||
| Q2 25 | — | 58.9% | ||
| Q1 25 | — | 58.0% | ||
| Q4 24 | — | 56.5% | ||
| Q3 24 | 17.7% | 58.5% | ||
| Q2 24 | 16.5% | 59.1% |
| Q1 26 | — | — | ||
| Q4 25 | 7.2% | 14.2% | ||
| Q3 25 | 11.6% | 16.7% | ||
| Q2 25 | 8.0% | 18.0% | ||
| Q1 25 | 7.4% | 14.9% | ||
| Q4 24 | 0.2% | 13.2% | ||
| Q3 24 | 7.4% | 16.8% | ||
| Q2 24 | 6.8% | 3.9% |
| Q1 26 | 5.7% | — | ||
| Q4 25 | 6.0% | 8.7% | ||
| Q3 25 | 9.5% | 10.6% | ||
| Q2 25 | 6.4% | 10.9% | ||
| Q1 25 | 5.8% | 8.6% | ||
| Q4 24 | -1.0% | 8.0% | ||
| Q3 24 | 6.5% | 9.8% | ||
| Q2 24 | 5.4% | 1.5% |
| Q1 26 | $0.77 | — | ||
| Q4 25 | $0.73 | $0.16 | ||
| Q3 25 | $1.18 | $0.21 | ||
| Q2 25 | $0.76 | $0.22 | ||
| Q1 25 | $0.63 | $0.17 | ||
| Q4 24 | $0.23 | $0.16 | ||
| Q3 24 | $0.65 | $0.20 | ||
| Q2 24 | $0.51 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $730.0M | $1.1B |
| Total DebtLower is stronger | $7.0B | — |
| Stockholders' EquityBook value | $5.6B | $10.8B |
| Total Assets | $19.8B | $27.1B |
| Debt / EquityLower = less leverage | 1.25× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $730.0M | — | ||
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $568.0M | $1.1B | ||
| Q2 25 | $296.0M | $1.1B | ||
| Q1 25 | $449.0M | $1.1B | ||
| Q4 24 | $885.0M | $1.1B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.3B | $1.0B |
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | — | ||
| Q3 25 | $6.9B | — | ||
| Q2 25 | $6.5B | — | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.5B | — |
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.4B | $10.8B | ||
| Q3 25 | $5.4B | $10.6B | ||
| Q2 25 | $5.2B | $10.7B | ||
| Q1 25 | $5.5B | $10.1B | ||
| Q4 24 | $5.9B | $9.7B | ||
| Q3 24 | $6.7B | $10.6B | ||
| Q2 24 | $6.9B | $10.2B |
| Q1 26 | $19.8B | — | ||
| Q4 25 | $19.5B | $27.1B | ||
| Q3 25 | $18.7B | $27.2B | ||
| Q2 25 | $18.6B | $27.1B | ||
| Q1 25 | $18.0B | $26.3B | ||
| Q4 24 | $17.6B | $25.6B | ||
| Q3 24 | $18.8B | $26.9B | ||
| Q2 24 | $19.0B | $26.4B |
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.29× | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | 0.80× | — | ||
| Q2 24 | 0.80× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $854.0M |
| Free Cash FlowOCF − Capex | $-938.0M | $744.0M |
| FCF MarginFCF / Revenue | -26.0% | 19.7% |
| Capex IntensityCapex / Revenue | 4.5% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | $596.0M | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $854.0M | ||
| Q3 25 | $384.0M | $294.0M | ||
| Q2 25 | $332.0M | $621.0M | ||
| Q1 25 | $-665.0M | $428.0M | ||
| Q4 24 | $500.0M | $793.0M | ||
| Q3 24 | $610.0M | $249.0M | ||
| Q2 24 | $252.0M | $440.0M |
| Q1 26 | $-938.0M | — | ||
| Q4 25 | $1.0B | $744.0M | ||
| Q3 25 | $257.0M | $196.0M | ||
| Q2 25 | $236.0M | $533.0M | ||
| Q1 25 | $-746.0M | $249.0M | ||
| Q4 24 | $393.0M | $661.0M | ||
| Q3 24 | $493.0M | $190.0M | ||
| Q2 24 | $146.0M | $350.0M |
| Q1 26 | -26.0% | — | ||
| Q4 25 | 31.1% | 19.7% | ||
| Q3 25 | 7.6% | 5.2% | ||
| Q2 25 | 7.1% | 13.9% | ||
| Q1 25 | -24.1% | 6.7% | ||
| Q4 24 | 13.6% | 18.1% | ||
| Q3 24 | 16.0% | 4.9% | ||
| Q2 24 | 4.9% | 8.8% |
| Q1 26 | 4.5% | — | ||
| Q4 25 | 5.1% | 2.9% | ||
| Q3 25 | 3.8% | 2.6% | ||
| Q2 25 | 2.9% | 2.3% | ||
| Q1 25 | 2.6% | 4.8% | ||
| Q4 24 | 3.7% | 3.6% | ||
| Q3 24 | 3.8% | 1.5% | ||
| Q2 24 | 3.6% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 6.05× | 2.59× | ||
| Q3 25 | 1.20× | 0.74× | ||
| Q2 25 | 1.54× | 1.48× | ||
| Q1 25 | -3.72× | 1.33× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | 3.07× | 0.65× | ||
| Q2 24 | 1.58× | 7.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BALL
| Beverage packaging, North and Central America | $1.8B | 49% |
| Beverage packaging, EMEA | $1.1B | 31% |
| Beverage packaging, South America | $585.0M | 16% |
| Other | $131.0M | 4% |
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
